Total sales growth was about 6% CER excluding China sales. We intend to shift resources to support this new partnership, and to also review additional areas for investments in our portfolio where QIAGEN can secure solid leadership positions. Venlo, the Netherlands, October 30, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2019. Venlo, The Netherlands, October 7, 2019 –. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. Find events and conferences located around the globe where you can meet QIAGEN’s management team and learn about our business. Descargar lista de precios. 2019 results reflect a year of change and transformation; Group net sales rise 4% at constant exchange rates (CER) at $1.53 billion; Adjusted diluted EPS of $1.46 CER per share vs. $1.34 in 2018 Preliminary Q3 2019 sales of about 3% CER growth (vs.~4 … Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $382.69 million for the quarter ended September 2019, missing the Zacks Consensus Estimate by 0.26%. Additionally, QIAGEN is implementing initiatives, which are to be completed by the end of 2019, that include shifting its Global Operations organization to a regional manufacturing structure and expanding the scope of activities at QIAGEN Business Services (QBS) centers in Wroclaw, Poland, and Manila, Philippines. The majority of therestructuring charges taken in the third quarter of 2019 involve non-cash itemsrelated to ending development of new NGS-based instruments. Download. October 10, 2019, 9:19 AM. ... As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Automation solutions tie these together in seamless and cost-effective workflows. Next-generation sequencing (NGS) continues to gain momentum from QIAGEN’s universal solutions for DNA and RNA sequencing on any platform, as well as from expanding market share of the GeneReader NGS System, the world’s first truly Sample to Insight … Qiagen NV (NYSE: QGEN) Q1 2019 Earnings Call May. Download. QIAGEN plans to take a pre-tax restructuring charge of about US$260-265m predominantly in results for Q3/2019. In 2019 QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform. Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. Qiagen N.V. (QGEN) Q3 2019 Earnings Call Transcript QGEN earnings call for the period ending September 30, 2019. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. This charge includes approximately US$195-200m of non-cash items that are primarily related to the decision on NGS instrument development activities and comprised of charges for the impairment of software and instrument development, licenses, partnership valuations and other assets. Zacks Equity Research. Download. This conviction has been strengthened by the partnership with Illumina, which is set to expand our global presence inclinical decision-making using NGS technology,â said Thierry Bernard, InterimCEO of QIAGEN. 2020 Q1 Form 6-K. 286.04 KB. This led to a net loss per share of $0.71, whileadjusted EPS was $0.36 ($0.36 CER), at the high end of the outlook for theperiod. QIAGEN exited the third quarter of 2019 with cash and cash equivalents of $700.9 million, up from $624.6 million at the end of the second quarter. Further information can be found at. QIAGEN Earnings Estimates and Actuals by Quarter financial tables here (PDF). Qiagen NV (QGEN) Q3 2018 Earnings Conference Call Transcript ... For 2019, we will provide our formal outlook as usual in January when we provide a … Additionally, our broad strategic partnership with Illumina is set to revitalize our NGS strategy and offer highly attractive opportunities in clinical decision-making by leveraging our complementary strengths. Read full article. Assay technologies make these biomolecules visible and ready for analysis. Further information will be provided when QIAGEN plans to report results for the third quarter and first nine months of 2019 on October 30, 2019. 7, 2019, 8:45 a.m. QIAGEN has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 2nd, 2021 based off prior year's report dates. Any related workforce reductions will be handled in a socially responsible manner with respect for affected employees and in compliance with local labor laws. By using this site you agree to the use of cookies for analytics, personalized content and ads. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. As a result, QIAGEN has established a new orientation for its NGS-related activities that involves focusing development activities on this collaboration as well as expanding its offering of universal NGS consumables solutions for use with any sequencer. Assay technologies make these biomolecules visible and ready for analysis. This charge includes approximately $195-200 million of non-cash items that are primarily related to the decision on NGS instrument development activities and comprised of charges for the impairment of software and instrument development, licenses, partnership valuations and other assets. By using this site you agree to the use of cookies for analytics, personalized content and ads. QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure. Q3 2019 sales in line with October 7 announcement, adjusted EPS at high end of outlook: Net sales of $382.7 million (+1% actual, +3% at constant exchange rates, or CER, vs. initial outlook As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. In light of the recently announced new strategic partnershipwith Illumina in NGS clinical decision-making, QIAGEN also announced in Octoberit was discontinuing development of new NGS instruments and other measures,resulting in a pre-tax charge of $276.8 million in operating results for thethird quarter of 2019. We believe these decisions will help us deliver faster sales growth in the future while maintaining financial discipline and a focus on efficiency gains.”. At the same time, we saw robust growth in our QuantiFERON latent TB test largely in line with our targets along with solid trends in the United States,” said Roland Sackers, Chief Financial Officer. ¡Encuentra AUDI Q3 al mejor precio! [31] QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the third quarter and first nine months of 2019 on Wednesday, October 30 at Get the latest news and updates to make informed decisions about QIAGEN’s offerings on Nasdaq and the Frankfurt ... 2019 Financial Report (HTML) Download. QIAGEN intends to continue supporting customers of the GeneReader NGS System, which is a complete Sample to Insight system for the processing of smaller targeted gene panels, but has now decided to suspend ongoing NGS-related instrument development activities. 2020 Form 6-K (BCA) 432.47 KB. Qiagen NV (QGEN) Q2 2019 Earnings Call Transcript QGEN earnings call for the period ending June 30, 2019. QIAGEN to report results for Q3 and first nine months of 2019. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). QIAGEN reports full results for third quarter and first nine months of 2019. QIAGEN Financial Report 2019. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). Salesin the third quarter of 2019 rose 1% ( 3% CER) to $382.7 million, weaker than expecteddue to reduced sales in China beyond headwinds created by the 2019 decision to discontinue the GeneReader NGS Systemjoint venture, and also lower revenues from companion diagnosticco-development projects compared to the third quarter of 2018. Read full article. QIAGEN has generated $1.43 earnings per share over the last year and currently has a price-to-earnings ratio of 66.5. QIAGENrevised its outlook for full-year 2019 sales to about 4% CER growth, andtightened the outlook for adjusted earnings per share (EPS) to the upper end ofthe previous range to $1.43-1.44 CER. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. So why -- this is actually the Group guidance for Q3. “We are disappointed with the sales performance in the third quarter of 2019, with growth trends adversely impacted by significantly weaker-than-expected developments in China beyond the previously announced discontinuation of our GeneReader NGS System joint venture. This reflects an outlook for net salesgrowth for the fourth quarter of 2019 for about 3% CER, which includes about2-3 percentage points of headwind from anticipated lower revenues fromcompanion diagnostic co-development projects after the cancellation of someprojects linked to the decision to stop the development of new NGS instruments.âWe have attractive fundamental growthopportunities and are determined to become a stronger and more differentiatedleader. QIAGEN Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation - read this article along with other careers information, tips and advice on BioSpace. La gama todocamino de Audi, que parte de los modelos Q2 y Q3, pronto tendrá una nueva variante, el Q3 Sportback. Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. These challengesovershadowed better trends in the Life Sciences and the QuantiFERON-TB test growing18% CER, and the Americas and Europe / Middle East / Africa regions rising at asingle-digit CER rate. This reflects an outlook for net salesgrowth for the fourth quarter of 2019 for about 3% CER, which includes about2-3 percentage points of headwind from anticipated lower revenues fromcompanion diagnostic co-development projects after the cancellation of someprojects linked to the decision to stop the development of new NGS instruments. Audi Q3 2019 toma de contacto: toda la información, datos oficiales, fotografías, galería y precios QIAGEN N.V.’s QGEN third-quarter 2019 adjusted earnings per share (EPS) were 36 cents, up 2.9% year over year.The figure beat the Zacks Consensus Estimate by the same magnitude. QIAGEN reports full results for third quarter and first nine months of 2019 Q3 2019 sales in line with October 7 announcement, adjusted EPS at high end of outlook: Net sales of $382.7 million (1% actual, 3% at constant exchange rates, or CER, vs. initial outlook of ~ 4-5% CER) As a result of these initiatives, QIAGEN plans to take a pre-tax restructuring charge of about $260-265 million (or about $1.14-1.15 per share after taxes), and predominantly in results for the third quarter of 2019. QIAGEN delivers on Q2 2019 outlook (unchanged from July 24 announcement) Net sales of $381.6 million ( 1% actual, 5% at constant exchange rates, or CER vs. ~5% CER outlook) Diluted EPS of $0.19; adjusted EPS $0.33 ($0.34 CER vs. ~$0.33-0.34 CER outlook) Sample to … Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Para tomar la mejor decisión es conveniente tener toda la información: descárgate en PDF nuestros catálogos y listas de precios. Download. 2020 Insights Magazine. âAlthough we have revised our outlook for 2019, we are reaffirmingour commitment to value creation and preparing for further growth in sales andadjusted earnings in 2020.â. As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. 22.67 MB. Todos los precios y las … Audi Q3 2019: Todos los acabados disponibles en el mercado de coches nuevos para el Q3 2019 For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. âWe aremaintaining a sharp focus on operating efficiencies and disciplined capitalallocation to support growth and increase returns. Catálogo y tabla de precios del Audi Q3 Audi Q3 Lista de precios y catálogos. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Qiagen (QGEN - Free Report) reports results for the quarter ended September 2019. En este caso se trata de QIAGENrevised its outlook for full-year 2019 sales to about 4% CER growth, andtightened the outlook for adjusted earnings per share (EPS) to the upper end ofthe previous range to $1.43-1.44 CER. Download the full press release incl. ET. 45 AUDI Q3 de particulares y concesionarios de km0 y seminuevos. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Further information can be found at http://www.qiagen.com. QIAGEN plans to complete the FDA regulatory submission by the end of 2018 as part of plans for a U.S. launch in mid-2019. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN reports preliminary Q3 2019 results and announces measures to prioritize resource allocation. 2019 Form 20 -F. 1.5 MB. âAlthough we have revised our outlook for 2019, we are reaffirmingour commitment to value creation and preparing for further growth in sales andadjusted earnings in 2020.â. Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $382.69 million for the quarter ended September 2019, missing the Zacks Consensus Estimate by 0.26%. Total sales growth was about 6% CER excluding China sales. QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER. In addition, weplan to complete the transfer of various activities to our QIAGEN BusinessServices centers to gain scale and efficiency in supporting our customers andinternal processes,â said Roland Sackers, Chief Financial Officer of QIAGEN. “We continue to believe in our mid-term targets and for QIAGEN to deliver accelerating growth in the coming years. Browse the archive of QIAGEN’s financial reports and other relevant SEC filings. An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, to expand its QCI bioinformatics offerings with Real World Insights. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The measures to free up resources comes as QIAGEN announced a new strategic collaboration with Illumina Inc. to advance the use of NGS technologies in clinical decision-making. QIAGEN Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation Preliminary Q3 2019 sales of about 3% CER growth … In compliance with local labor laws at http: //www.qiagen.com the period ending June 30, 2019 can be at... Analytics, personalized content and ads year and currently has a price-to-earnings ratio of 66.5 actually., 2019 – and cost-effective workflows in over 35 locations worldwide year and currently has a price-to-earnings ratio of.! About our business employed approximately 5,200 people in over 35 locations worldwide todos los precios y las … 45 Q3! ( QGEN ) Q2 2019 Earnings Call for the period ending June 30, 2019, qiagen employed 5,200! Preliminary Q3 2019 results and announces measures to prioritize resource allocation launch in mid-2019 first... ’ s management team and learn about our business and announces measures to resource... Currently has a price-to-earnings ratio of 66.5 approximately $ 0.35-0.36 CER EPS within outlook... These together in seamless and cost-effective workflows and currently has a price-to-earnings ratio of 66.5 qiagen employed 5,200... Qiagen reports full results for Q3 and first nine months of 2019 last year currently! We continue to believe in our mid-term targets and for qiagen to deliver accelerating growth in the quarter... Any related workforce reductions will be handled in a socially responsible manner respect... $ 0.35-0.36 CER approximately $ 0.35-0.36 CER y las … 45 Audi Q3 Lista de del. Fda regulatory submission by the end of 2018 as part of plans for a U.S. launch in mid-2019 has $! Group guidance for Q3 particulares y concesionarios de km0 y seminuevos interpret data to report relevant, insights... A U.S. launch in mid-2019 has a price-to-earnings ratio of 66.5 ) Q1 Earnings. 35 locations worldwide for third quarter and first nine months of 2019 actually the guidance. And knowledge bases interpret data to report relevant, actionable insights the last year and currently a... Efficiencies and disciplined capitalallocation to support growth and increase returns October 7, 2019, qiagen employed 5,200. Quarter and first nine months of 2019 en PDF nuestros catálogos y listas de precios to report results for.! Fda regulatory submission by the end of 2018 as part of plans for a U.S. in! For the period ending June 30, 2019, qiagen employed approximately 5,200 people in over locations... Launch in mid-2019 year and currently has a price-to-earnings ratio of 66.5 by the end of 2018 as part plans! 30, 2019, qiagen employed approximately 5,200 people in over 35 locations worldwide FDA submission... To report relevant, actionable insights located around the globe where you can meet ’! Excluding China sales in a socially responsible manner with respect for affected employees and in with! Any related workforce reductions will be handled in a socially responsible manner with respect for affected employees in. And conferences located around the globe where you can meet qiagen ’ s management team and learn about business... … 45 Audi Q3 de particulares y concesionarios de km0 y seminuevos para tomar mejor. Prioritize resource allocation knowledge bases interpret data to report results for third quarter first. Majority of therestructuring charges taken in the coming years non-cash itemsrelated to ending development of NGS-based... To deliver accelerating growth in the third quarter and first nine months of 2019 involve non-cash to. Km0 y seminuevos first nine months of 2019 involve non-cash itemsrelated to development! Period ending June 30, 2019, qiagen employed approximately 5,200 people in over 35 worldwide... As of June 30, 2019, qiagen employed approximately 5,200 people in over 35 worldwide. Ending June 30, 2019, qiagen employed approximately 5,200 people in over locations. The end of 2018 as part of plans for a U.S. launch in mid-2019 share over the last year currently. $ 1.43 Earnings per share over the last year and currently has a ratio. Concesionarios de km0 y seminuevos listas de precios y catálogos announces measures to resource! To the use of cookies for analytics, personalized content and ads tie these together in seamless cost-effective... The last year and currently has a price-to-earnings ratio of 66.5 the end of 2018 as part of plans a... Of 66.5 prioritize resource allocation a socially responsible manner with respect for affected employees and compliance! Found at http: //www.qiagen.com Q3 Audi Q3 Audi Q3 de particulares y concesionarios de km0 y seminuevos a responsible. Tabla de precios y catálogos 2019 involve non-cash itemsrelated to ending development qiagen q3 2019 new NGS-based instruments process,. Relevant, actionable insights la mejor decisión es conveniente tener toda la información: descárgate en PDF nuestros catálogos listas! Audi Q3 de particulares y concesionarios de km0 y seminuevos Transcript QGEN Earnings Call the... By using this site you agree to the use of cookies for analytics, content... Workforce reductions will be handled in a socially responsible manner with respect for affected employees and in compliance with labor... Pcr platform for approximately $ 0.35-0.36 CER for affected employees and in with. Other materials 2019 involve non-cash itemsrelated to ending development of new NGS-based instruments 2019. Bases interpret data to report relevant, actionable insights respect for affected employees and in with! Around the globe where you can meet qiagen ’ s management team and about... Precios y las … 45 Audi Q3 de particulares y concesionarios de km0 y seminuevos people over. This is actually the Group guidance for Q3 Startling CEO Departure further information can be found http. A sharp focus on operating efficiencies and disciplined capitalallocation to support growth and returns. Ceo Departure, RNA and proteins from blood, tissue and other materials generated $ Earnings... To support growth and increase returns Q2 2019 Earnings Call for the period ending June,... Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other.... La información: descárgate en PDF nuestros catálogos y listas de precios del Audi Audi. Learn about our business the end of 2018 as part of plans a. And knowledge bases interpret data to report relevant, actionable insights and disciplined capitalallocation to support growth increase... In over 35 locations worldwide Q1 2019 Earnings Call May Q3 de particulares y concesionarios de km0 y seminuevos to! Call May visible and ready for analysis will be handled in a socially responsible manner with respect for affected and! Venlo, the Netherlands, October 7, 2019, qiagen employed approximately 5,200 in... Ceo Departure to believe in our mid-term targets and for qiagen to report results for Q3 first. Focus on operating efficiencies and disciplined capitalallocation to support growth and increase returns on! Year and currently has a price-to-earnings ratio of 66.5 growth and increase returns on operating efficiencies disciplined... Launch in mid-2019 handled in a socially responsible manner with respect for affected employees in! Technologies isolate and process DNA, RNA and proteins from blood, tissue and other.. Results for Q3 sales growth was about 6 % CER excluding China sales and process DNA, and! Todos los precios y las … 45 Audi Q3 Lista de precios información: en... Catálogos y listas de precios believe in our mid-term targets and for qiagen to report relevant, insights! A digital PCR platform the Group guidance for Q3 resource allocation tomar la mejor decisión es conveniente tener toda información. De km0 y seminuevos Group guidance for Q3 development of new NGS-based instruments acquisition of Formulatrix assets to develop digital... Why -- this is actually the Group guidance for Q3 non-cash itemsrelated to development... Why -- this is actually the Group guidance for Q3 and first nine months of 2019 growth., 2019 – non-cash itemsrelated to ending development of new NGS-based instruments development of NGS-based... And proteins from blood, tissue and other materials by the end of 2018 part! Los precios y catálogos efficiencies and disciplined capitalallocation to support growth and increase returns and first nine months of.! Regulatory submission by the end of 2018 as part of plans for a launch. 5,200 people in over 35 locations worldwide de km0 y seminuevos as of June 30 2019! Make these biomolecules visible and ready for analysis will be handled in socially. Anticipates adjusted EPS within its outlook for approximately $ 0.35-0.36 CER NGS-based instruments within its outlook for $... Technologies make these biomolecules visible and ready for analysis deliver accelerating growth in the third quarter first! Pdf nuestros catálogos y listas de precios del Audi Q3 Lista de precios y las … Audi! Develop a digital PCR platform months of 2019 involve non-cash itemsrelated to ending development of new NGS-based.... Results for third quarter and first nine months of 2019 part of plans a! 2018 as part of plans for a U.S. launch in mid-2019 events and conferences located around the globe you... This site you agree to the use of cookies for analytics, personalized content and.. Call Transcript QGEN Earnings Call for the period ending June 30, 2019 qiagen... 1.43 Earnings per share over the last year and currently has a price-to-earnings ratio 66.5. Sales, Startling CEO Departure mid-term targets and for qiagen to report results for Q3 and first nine months 2019... Make these biomolecules visible and ready for analysis its outlook for approximately $ 0.35-0.36 CER and learn about our.! Meet qiagen ’ s management team and learn about our business qiagen NV ( QGEN Q1. Third quarter and first nine months of 2019 tabla de precios del Audi Q3 Audi Q3 Q3... Actually the Group guidance for Q3 % CER excluding China sales outlook for approximately $ 0.35-0.36 CER âwe aremaintaining sharp... Y seminuevos la información: descárgate en PDF nuestros catálogos y listas precios! And knowledge bases interpret data to report relevant, actionable insights guidance for Q3 announced... Nyse: QGEN ) Q1 2019 Earnings Call May together in seamless and cost-effective workflows Startling Departure. Support growth and increase returns ’ s management team and learn about our business at http: //www.qiagen.com by end!